Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue
MWN-AI** Summary
Cosmos Health Inc. (NASDAQ:COSM) has reported significant operational growth and infrastructure enhancement at its Greek pharmaceutical distribution subsidiary, Cosmofarm. In 2025, Cosmofarm welcomed nearly 100 new pharmacy clients, resulting in a 20% increase in its active customer base. This expansion coincided with improved unit economics, with annual revenue per customer rising by 12% and profitability per customer growing by 14%. The company attributes these gains to better route density, optimized order execution, and enhanced operational leverage. Management expects customer growth to maintain or exceed these levels in 2026.
To bolster service quality and delivery capabilities, Cosmofarm has implemented three new delivery routes within Attica, a major pharmaceutical market in Greece. The company's operational framework is backed by multi-million investments in automation, notably advanced robotic systems for procurement and order fulfillment. An ongoing capital investment program of approximately $1 million aims to further enhance robotic capacity and processing throughput.
A newly proposed master plan highlights the integration of expanded robotic picking lines designed to significantly increase processing capacity and support an additional $40 million in annual revenue potential through enhanced distribution capabilities. In parallel, Cosmofarm is modernizing its 29,000-square-foot facility in Athens, optimizing office spaces and expanding temperature-controlled storage areas to facilitate future growth.
CEO Greg Siokas emphasized the significance of these developments, highlighting that cosmopolitan corporate strategy relies on strong customer acquisition, improved unit economics, and operational efficiency. The ongoing investment in automation positions Cosmofarm as a critical asset for sustainable growth and long-term value creation for Cosmos Health. The company also maintains a diverse portfolio of proprietary pharmaceutical brands and is expanding its presence globally through strategic R&D partnerships and its entry into telehealth services.
MWN-AI** Analysis
Cosmos Health Inc. (NASDAQ:COSM) has reported robust operational growth, highlighted by the addition of nearly 100 new customers at its pharmaceutical distribution subsidiary, Cosmofarm. This 20% increase in the active customer base, supported by improved unit economics (12% increase in revenue per customer and 14% increase in profitability per customer), positions the company for a strong 2026.
The forward momentum stems from enhanced order execution, strategic route density optimizations, and a growing investment in automation. Importantly, Cosmos Health's significant infrastructure developments, including advanced robotic systems for inventory management, are projected to generate an additional $40 million in annual revenue. This kind of investment signals a company committed to maintaining a competitive edge in the fast-evolving healthcare sector.
As the European pharmaceutical market continues to grow, particularly in regions like Greece, Cosmos Health's strategic initiatives reveal sound operational execution and a focus on scalability. The addition of delivery routes in densely populated Attica indicates a commitment to improving service quality and customer satisfaction, critical metrics that often lead to increased loyalty and further growth opportunities.
From an investment standpoint, Cosmos Health presents an attractive opportunity, especially given the dual focus on organic growth through increased customer acquisition and streamlined operations through automation. However, potential investors should also consider the risks highlighted in their forward-looking statements, including market volatility and the company's ability to navigate macroeconomic challenges, such as geopolitical events.
Overall, Cosmos Health appears well-positioned to capitalize on its current trajectory, making it a stock to watch for those interested in the healthcare sector. Investors should continue monitoring performance trends and broader market conditions while evaluating their positions in COSM.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued operational growth and infrastructure expansion at Cosmofarm, its pharmaceutical distribution subsidiary in Greece.
During 2025, Cosmofarm added nearly 100 new pharmacy customers, representing a weighted average increase of approximately 20% in its active customer base. This growth was accompanied by improved unit economics, with annual revenue per customer increasing by approximately 12% and profitability per customer improving by approximately 14%, driven by enhanced route density, optimized order execution, and increasing operational leverage. Based on current onboarding activity and demand trends, management expects customer growth in 2026 to continue at similar or higher rates.
To further strengthen service quality and last-mile delivery performance, Cosmofarm introduced three new delivery routes within the Attica region, expanding geographic coverage and delivery frequency across one of Greece’s most densely populated pharmaceutical markets.
Cosmofarm’s operating model is supported by multi-year, multi-million investments in automation and logistics infrastructure, including advanced ROWA and A-frame robotic systems for procurement, inventory management, and order fulfillment. A further capital investment program of approximately $1 million is currently underway, continuing prior initiatives to expand robotic capacity and throughput.
ROWA and A-Frame Picking Line Extension Master Plan
The image above illustrates the master plan of the expanded ROWA and A-frame robotic picking line, highlighting an integrated automation layout designed to materially increase processing capacity, enhance accuracy and speed, and support incremental annual revenue potential of approximately $40 million through expanded distribution capability.
In addition to these initiatives, Cosmofarm continues to upgrade its wholly owned 29,000-square-foot property in Athens, pictured below, with modernized office space, expanded distribution areas, and enhanced temperature-controlled storage, to support the next phase of the Company’s growth.
Greg Siokas, CEO of Cosmos Health, stated: “Cosmofarm continues its record-setting momentum, reflecting strong execution across customer acquisition, improving unit economics, and operational efficiency. Our ongoing investment in advanced automation significantly expands capacity and positions the platform to support incremental annual revenue potential of approximately $40 million as volumes scale. As we expand robotic infrastructure and last-mile capabilities, Cosmofarm remains a strategically important asset supporting sustainable growth and long-term value creation for Cosmos Health.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
Images accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/ab4534aa-b578-4985-aa6d-2293410064a2
https://www.globenewswire.com/NewsRoom/AttachmentNg/d418386a-a1e1-4945-8ad6-eec912b084e1
Disclaimer
This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a COSM financial position. COSM financial position and all other information regarding the featured Company should be verified directly with COSM. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in COSM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of COSM shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Compensation: Market Wire News and its affiliates has received six thousand dollars for Market Wire News advertising services from Relqo Media LLC for Brand Awareness Distribution, Corporate Communications, News, Press Release Enhancement and Social Media Solutions starting 2026-05-31 and ending 2026-06-05 provided by Market Wire News. To date, we have received a total of six thousand dollars. Please read our full disclaimer for compensation and more detailed information.
FAQ**
How does Cosmos Holdings Inc. COSM plan to maintain its growth trajectory in customer acquisition following the addition of nearly 100 new pharmacy customers through its subsidiary Cosmofarm in 2025?
What specific advancements in automation and logistics is Cosmos Holdings Inc. COSM implementing to enhance its operational efficiency and support expected revenue growth in 2026?
Can Cosmos Holdings Inc. COSM elaborate on the anticipated impact of their $1 million capital investment program on delivery performance and service quality in the Greek pharmaceutical market?
Given the forward-looking statements, what risks does Cosmos Holdings Inc. COSM foresee that could affect its ability to achieve the incremental annual revenue potential of approximately $million from the expanded distribution capability?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Health Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
-3.36% G/L:
$0.2505 Last:
367,675 Volume:
$0.264 Open:
